breast cancer
Breast cancer patients benefit from blogging
September 2, 2013Medical Communications blogging, breast cancer
Breast cancer patients who discuss their personal experiences with the disease online can help both the authors and their audience. …
GSK and Roche get EU breast cancer indication
August 15, 2013Sales and Marketing GSK, Herceptin, Roche, Tyverb, Xeloda, breast cancer
The European Commission has granted a new indication for the use of GSK’s breast cancer drug Tyverb in combination with …
FDA gives Perjeta priority
July 3, 2013Sales and Marketing FDA, Perjeta, Roche, breast cancer
The FDA has granted priority review status to an application for Roche’s Perjeta to be used before surgery in HER2-positive …
Afinitor’s new UK indication launched
September 20, 2012Sales and Marketing Afinitor, CHMP, Novartis, breast cancer
Novartis’ cancer drug Afinitor has been made available in the UK for patients with the most common form of advanced …
Another NICE no for Avastin in breast cancer
August 22, 2012Sales and Marketing NICE, avastin, breast cancer, rejection
Roche’s Avastin has been rejected once again for use in breast cancer patients. NICE has now issued final guidance saying …
Roche winning on Perjeta supply, but running short of Boniva
August 20, 2012Manufacturing and Production, Sales and Marketing Boniva, Perjeta, Roche, breast cancer
Roche is getting production for its new breast cancer drug Perjeta back on track after some initial teething troubles, but …
NICE no for Avastin in breast cancer
July 6, 2012Sales and Marketing NICE, Roche, avastin, breast cancer, rejection
NICE has decided once again not to recommend Roche’s Avastin on the NHS for the first line treatment of metastatic …
Roche’s Perjeta increases survival
June 27, 2012Research and Development, Sales and Marketing EMA, FDA, Herceptin, Perjeta, Roche, breast cancer
Roche’s new drug Perjeta has scored another trial success by increasing overall survival in certain breast cancer patients. The new …
FDA approves Roche’s breast cancer drug
June 11, 2012Sales and Marketing EMA, FDA, Perjeta, Roche, breast cancer
US regulators have approved Roche’s new breast cancer drug after granting it a priority review to speed up the process. …
NICE rejects Avastin for breast cancer
April 18, 2012Sales and Marketing EMA, NICE, Roche, avastin, breast cancer
In a blow for Roche, NICE has turned down its cancer drug Avastin because of ‘too many uncertainties’ over cost …
NICE rejects Halaven for breast cancer
April 3, 2012Sales and Marketing Eisai, Halaven, NICE, breast cancer
NICE has rejected Eisai’s novel breast cancer drug Halaven, due to concerns over its safety and costs. In its final …
Breast cancer treatment – the next advances
February 7, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Afinitor, CDF, Lorena Tonarelli, T-DM1, breast cancer, pertuzumab
When a close member of my family was diagnosed with breast cancer, the doctors didn’t give us much hope. They …
GSK’s Tyverb fails late-stage trial in breast cancer
December 12, 2011Research and Development, Sales and Marketing GSK, Tyverb, breast cancer
GlaxoSmithKline’s Tyverb has failed to help women with HER2 positive breast cancer increase their survival. The TEACH study’s primary objective …
Roche’s new breast cancer drug succeeds in late-stage trial
December 9, 2011Research and Development, Sales and Marketing Roche, breast cancer, pertuzumab
Roche’s next generation breast cancer drug pertuzumab has helped patients to live over six months longer. CLEOPATRA, the first randomised …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
